Name |
Soluble CD163 (sCD163) |
Alternative name/Profile |
ANCA-associated vasculitis, AAV |
Department |
Immunology |
Investigation |
ELISA (EUROIMMUN sCD163) |
Specimen type |
Random Urine |
Sample type |
Random Urine |
Sample container & volume |
25mls of urine in a Universal Container |
Frequency of analysis |
Batch basis |
Turnaround time |
21 days |
Availability |
|
Notes |
Useful for:
- Evaluating patients with acute renal disease associated with increased activity of CD163 positive M2 macrophages. For example ANCA-associated vasculitis
Clinical Information:
- CD163 is a receptor that is exclusively expressed on monocytes and macrophages and is a specific marker of anti-inflammatory M2 macrophages
- Pro-inflammatory stimuli result in cleavage of CD163, thus soluble CD163 (sCD163) is a biomarker of inflammation
- Increased plasma sCD163 concentrations can be found in patients with acute and chronic inflammatory conditions
- Significantly increased sCD163 levels in urine are found in patients with active ANCA-associated vasculitis and lupus nephritis
- Slightly increased levels may be found in patients with acute kidney failure, and in patients with ANCA-associated vasculitis that is in remission or without kidney involvement
Please Note:
- In patients with proteinuria, sCD163 levels must be interpreted with caution as sCD163 can pass from the blood into the urine
- Where External Institiutions cannot guarantee immediate delivery, samples must be centrifuged for 5 minutes at 1500rpm then separated. Separated samples may be stored for 1 week at 40C or, for a storage time exceeding this, they should be frozen at a minimum of -200C. Samples can then be transported (if frozen, transport on dry ice) to St. James's Hospital for processing
|
Related links |
|
Reference range |
sCD163 normalised to creatinine (ng/mmol):
Normal: 0 - 250
Equivocal: 251 - 500
Abnormal: >500
Normal Reference Ranges for CD163 assay established in conjunction with Rare Kidney Disease Registry and Biobank as part of large research project within the TTMI (Trinity Translational Medicine Institute) 2019 |
Last updated |
Wed, 15 Mar 2023 12:04:37 GMT |